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Context: Autoimmune polyendocrine syndrome type 1 (APS1) is a childhood-onset monogenic disease defined
by the presence of two of the three major components: hypoparathyroidism, primary adrenocortical insuffi-
ciency, and chronic mucocutaneous candidiasis (CMC). Information on longitudinal follow-up of APS1 is sparse.
Objective: To describe the phenotypes of APS1 and correlate the clinical features with autoantibody profiles and
autoimmune regulator (AIRE) mutations during extended follow-up (1996–2016).
Patients: All known Norwegian patients with APS1.
Results: Fifty-two patients from 34 families were identified. The majority presented with one of the major disease
components during childhood. Enamel hypoplasia, hypoparathyroidism, and CMC were the most frequent compo-
nents.Withage,mostpatientspresentedthreetofivediseasemanifestations,althoughsomehadmilderphenotypes
diagnosed in adulthood. Fifteen of the patients died during follow-up (median age at death, 34 years) or were
deceasedsiblingswithahighprobabilityofundisclosedAPS1.Allexceptthreehadinterferon-)autoantibodies,and
allhadorgan-specificautoantibodies.ThemostcommonAIREmutationwasc.967_979del13, foundinhomozygosity
in 15 patients. A mild phenotype was associated with the splice mutation c.8791GA. Primary adrenocortical
insufficiency and type 1 diabetes were associated with protective human leucocyte antigen genotypes.
Conclusions: Multiple presumable autoimmune manifestations, in particular hypoparathyroidism, CMC, and
enamel hypoplasia, should prompt further diagnostic workup using autoantibody analyses (eg, interferon-)
and AIRE sequencing to reveal APS1, even in adults. Treatment is complicated, and mortality is high. Structured
follow-up should be performed in a specialized center. (J Clin Endocrinol Metab 101: 2975–2983, 2016)
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Autoimmune polyendocrine syndrome type 1 (APS1) isa monogenic disease, also known as autoimmune
polyendocrinopathy-candidiasis-ectodermal dystrophy
(OMIM no. 240300). Clinically, APS1 is defined by the
presence of two of the three major components: hypo-
parathyroidism, primary adrenocortical insufficiency
(PAI), and chronic mucocutaneous candidiasis (CMC) (1).
However, the syndrome also includes many less known
disease components, and the clinical presentation is highly
variable (2). One major manifestation combined with a
sibling with APS1 also qualifies for the diagnosis. The
disease usually presents in childhood and adolescence, but
many patients are not diagnosed until adulthood or not at
all (3). APS1 patients have an increased risk of cancer and
increased mortality compared with the general population
(4). The diagnosis can also be made by finding two disease-
causing mutations in the autoimmune regulator (AIRE)
gene together with clinical manifestations (5, 6). About
115 mutations have been reported so far (7). AIRE is al-
most exclusively expressed in the thymus (8) and plays a
crucial role in negative selection of self-reactive T cells and
development of regulatory T cells (9, 10).
The highest prevalence is found among Persian Jews
(1:9000) (11), Sardinians (1:14 000) (12), and Finns (1:
25 000) (1). The prevalence in Norway was previously
reported at 1:90 000 (3). Recently, patients with mono-
allelic AIRE mutations with dominant inheritance, char-
acterized by a later disease onset and often milder pheno-
types, were reported (13). These nonclassical forms may
be much more prevalent because monoallelic AIRE mu-
tations have a prevalence in the general population of
about 1:1000 (13).
Most patients have autoantibodies against autoanti-
gens expressed in the affected tissue (14), eg, the steroid-
ogenic enzymes 21-hydroxylase (21OH) in the adrenal
cortex and side-chain-cleavage enzyme (SCC) in the go-
nads and adrenal cortex. Recently, several novel autoan-
tigens have been identified using proteome arrays, includ-
ing the prostate-specific enzyme transglutaminase 4
(TGM4) associated with male infertility and prostatitis in
Aire-knockout mice (15, 16). Other autoantigens identi-
fied using this technique include protein disulfide isomer-
ase-like testis expressed (PDILT) and melanoma antigen
B2 (MAGEB2), which are both expressed in testicular
germ cells (17). In addition, almost all patients display
autoantibodies to interferons (IFNs) and interleukins (ILs)
(18, 19); they typically appear years before the corre-
sponding clinical symptoms. Mutational analysis and as-
say of anti-IFN- autoantibodies are suggested as diag-
nostic options (20).
Information on longitudinal follow-up of APS1 pa-
tients is sparse, with only a few series published (21–23).
Building on previous surveys of the Norwegian cohort and
our National Registry of Autoimmune Diseases (3, 24), we
here provide a longitudinal follow-up of the Norwegian
cohort spanning two decades and presenting the natural




Patients were recruited from departments of medicine and
pediatrics from hospitals in Norway and were included in our
National Registry of Autoimmune Diseases initiated in 1996 (3).
All fulfilled the diagnostic criteria for APS1 given above. The
Regional Committee for Medical and Health Research Ethics
approved the study, and all participants gave informed consent.
Definitions and clinical data
The patients were assessed at least annually, including hor-
monal status and autoantibody profiles. All patients alive were
screened for AIRE mutations. A dental and oral examination
was performed in 31 patients, and most patients underwent
esophagogastroduodenoscopy, chest x-ray, and imaging of the
spleen and kidneys. Endocrinopathies were diagnosed as previ-
ously described (1). The diagnostic criteria for other disease man-
ifestations are given in Supplemental Table 1.
Autoantibody assays
Autoantibodies against 21OH, 17--hydroxylase (17OH),
aromatic L-amino acid decarboxylase (AADC), glutamic acid
decarboxylase 65-kDA isoform (GAD65), IFN-, IL-17, IL-22,
MAGEB2, NACHT leucine-rich-repeat protein 5, PDILT, pu-
tative potassium channel regulator, SCC, sex-determining region
Y-box 10, TGM4, tryptophan hydroxylase 1, and tyrosine hy-
droxylase were assayed by radio-binding ligand assay as de-
scribed previously (15, 16, 25). All autoantibody assays were
performed in our laboratory, and sera spanning a time period
were analyzed in the same experiment to avoid between-assay
variations in the indices. Parietal cell antigen autoantibodies
were assayed by ELISA (Euroimmun).
Mutational analysis of the AIRE gene
DNA sequencing of AIRE spanning the exon-intron bound-
aries was performed using standard methods. Primer sequences
are available upon request. Copy number analysis was per-
formed by duplex TaqMan real-time PCR as previously de-
scribed (26).
Human leukocyte antigen allele typing
The sequence-based human leukocyte antigen (HLA) geno-
typing was performed using SBT Resolver and Assign Software
(Conexio Genomics).
Statistical analyses
Fischer’s exact test with two-sided significance performed in
a 2  2 contingency table was used (IBM SPSS Statistics 22),
testing each autoantibody against the presence of different dis-
ease components. Similarly, the associations between pheno-
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types, AIRE mutations, and different HLA alleles were tested.
Specifically, we also investigated the correlation between PAI in
APS1 patients and HLA class II risk genotypes for PAI in the
general population as defined previously (27).
Results
APS1 patients ascertained
Applying our diagnostic criteria and the National Reg-
istry of Autoimmune Diseases, we included 52 individuals
(28 males, 24 females) from 34 families, including three
patients (Supplemental Table 2, family XXIX, patients no.
45–47) with monoallelic AIRE PHD1 mutations (Table
1). These patients represented all known Norwegian APS1
patients. Fifteen patients died during the follow-up period,
including seven who were identified only after their death.
Most of the patients participated in two earlier surveys (3,
24), but 12 identified after 2007 (3) were added to the
current survey.
Clinical manifestations and the classic triad
The clinical picture was highly variable, even among
members of the same family. An overview of the preva-
lence of the most common disease components, including
sex distribution and age at presentation, is given in Table
2 and Supplemental Table 2. The most common initial
manifestations were hypoparathyroidism (17 patients,
32%) and CMC (13 patients, 25%), but other compo-
nents occasionally presented first. Among patients with all
three major components, 14 (67%) had developed the
triad by 25 years of age. In general, the disease components
increased in prevalence by age, although the time courses
differed markedly (Figure 1). The median number of dis-
ease components was five (range, one to eight) (Supple-
mental Figure 1).
Two-thirds of the patients with hypoparathyroidism
were diagnosed before the age of 15 years. One young
female patient (patient 38) died of seizures at age 3 years,
probably from undiagnosed hypoparathyroidism.
Thirty patients with PAI (91%) were diagnosed before
age 25 years, including 21 (64%) before the age of 15
years. Two young females died in acute adrenal failure
during the follow-up period (Supplemental Table 3).
The clinical course of CMC varied from periodic to
chronic. Fourteen patients (27%) developed CMC before
Table 1. Basic Demographics of the 52 Norwegian
APS1 Patients
No. of females/males 24/28
No. of families 34
Age at onset of first component, y 0–43 (median, 8.5)
Age at death (n  15), y 3–64 (median, 34)
AIRE mutations found (alleles, n  92) 92% (85/92)
Autoantibodies (n  45)
Organ specific 100% (45/45)
IFN- 93% (42/45)







Age at Onset, y
Classic triad
Hypoparathyroidism 73 (38/52) 18/20 9 (1–60)
PAI 63 (33/52) 11/22 13 (4–55)
CMC 77 (40/52) 15/25 7,5 (0–64)
All three 40 (21/52) 6/15 14 (4–64)
Other endocrine disorders
Gonadal failure 33 (8/24)a 8/0 18 (15–25)
Diabetes mellitus 8 (4/52) 1/3 33 (23–54)
Hypothyroidism 19 (10/52) 8/2 22 (13–51)
Skin disorders
Alopecia 31 (16/52) 5/11 19 (4–41)
Vitiligo 15 (8/52) 4/4 20 (15–51)
Gastrointestinal disorders
Pernicious anemia or vitamin B12 deficiency 15 (8/52) 4/4 38 (13–63)
Malabsorption 23 (12/52) 5/7 21 (10–39)
Autoimmune hepatitis 4 (2/52) 0/2 5,5 (0–11)
Eye disorders
Keratoconjunctivitis 12 (6/52) 1/5 22 (11–25)
Others
Enamel hypoplasia 72 (18/25)b 9/9
Nail dystrophy 13 (7/52) 3/4
Asplenia 16 (5/31) 2/3
a Percentage of female patients.
b Percentage of patients examined by dentist.
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age 10 years and only three after the age of 30 years. Eleven
had angular cheilitis at the time of examination and an-
other 10 reported previous episodes. Eight patients (15%)
were diagnosed with candida esophagitis, sometimes
without typical symptoms or coexisting oral candidiasis.
One patient (patient 34) developed stenosis of the esoph-
agus requiring endoscopic dilation. Twelve of the 31 pa-
tients examined by a dentist tested positive for Candida
albicans by culture. One patient (patient 51) suffered from
severe candida otitis.
Other endocrinopathies
Hypothyroidism was the third most frequent endocri-
nopathy followed by gonadal failure. No male hypogo-
nadism was found. Diabetes mellitus type 1 was rare (n 
4) and had a relatively late onset.
Oral cavity and teeth
Six of 31 examined patients had extensive composite
dental restorations, most probably secondary to underly-
ing enamel defects. Another 18 (72%) had enamel hyp-
oplasia typical for APS1 (Figure 2),
and five had enamel hypomineraliza-
tion without enamel hypoplasia,
which could be of different etiology.
The enamel hypoplasia varied in ex-
tent and location. Nine patients had
gingivitis, and eight patients pre-
sented pathologically low (below 0.1
mL/min) unstimulated salivary flow.
Skin diseases
Vitiligo was variable in extent and
location, from spots to almost uni-
versal, but was not classified into
segmental or nonsegmental forms.
The time of diagnosis of alopecia was
highly variable, and the clinical
picture varied from chronic to
periodical.
Gastrointestinal manifestations
Chronic diarrhea was interpreted
as malabsorption. Pernicious ane-
mia and vitamin B12 deficiency typ-
ically presented late but were also
seen in some young individuals (pa-
tient 51). Autoimmune hepatitis was
found in two young male patients
(patients 12 and 42). Generally, the
gastrointestinal manifestations were
of variable intensity and duration.
Ocular disease
Three patients had keratoconjunctivitis, two iridocy-
clitis, and one blepharoconjunctivitis. A female patient
(patient 43) was diagnosed with optic neuritis at the age of
22 years.
Other manifestations
Two patients were diagnosed with tubulointersitial ne-
phritis. Patient 1 was diagnosed with IgA nephritis at age
15 years, and patient 17 presented with nephrotic syn-
drome at age 48 years. Biopsy showed local segmental
nephrosclerosis. Her kidney disease is now stable after
steroid treatment. Deafness was found in one female pa-
tient (patient 51).
The natural course
Most patients follow the classic course already de-
scribed for APS1: the first disease component, often one of
the classic triad components, presented in childhood, with
additional disease components occurring at different time
intervals (Figure 1 and Supplemental Table 2). However,
Figure 1. Disease histories of Norwegian APS1 patients. The lines start at birth and end at death
(bracket) or at current age (). Age at appearance of disease component is indicated by a symbol
of the disease. Disease components of uncertain time of onset are listed at the end of the line.
The major disease components CMC, HP, and PAI are marked in red, blue, and green,
respectively. Al, alopecia; AS, asplenia; AT, hypothyroidism; Ca, cancer; DM, diabetes mellitus; E,
enamel hypoplasia/defects; G, hypogonadism; H, hepatitis; HP, hypoparathyroidism; K,
keratoconjunctivitis; M, malabsorption; N, nail dystrophy; P, pancreas failure exocrine; PA,
pernicious anemia; PS, psoriasis; TIN, tubule interstinal nephritis; V, vitiligo.
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only 14 of 21 patients developed the full triad before the
age of 25 years. Early onset was associated with a more
severe phenotype, and the disease components increased
in prevalence with age. Hypoparathyroidism, PAI, CMC,
and autoimmune hepatitis appeared early, whereas hypo-
thyroidism, B12 deficiency, and pernicious anemia mainly
had a late onset. Furthermore, the vast majority of patients
had enamel defects or hypoplasia, probably with onset in
adolescence. Atypical late presentations and long intervals
between components contributed to delayed diagnosis
(patients 30, 31, and 46).
Mortality and cancer
Fifteen patients died during the follow-up period, and
seven patients were identified after their death (Supple-
mental Table 3). The major causes of death were malig-
nant disease and adrenal and hypocalcemic crises. The
median age at death was 34 years. Supplemental Table 4
gives an overview of the different malignant conditions
found.
Distribution of autoantibodies
We assayed a large panel of autoantibodies related to
APS1, including the recently identified autoantigens
TGM4, PDILT, and MAGEB2 (Supplemental Figure 2).
All 45 patients tested presented organ-specific autoanti-
bodies. In total, IFN- autoantibodies were found most
frequently (42 patients, 93%), followed by autoantibodies
against 21OH (71%) and IL-22 (71%). Notably, the pros-
tate-specific antigen TGM4 was found only in males (Sup-
plemental Figure 2 and Supplemental Table 2). Assay of
autoantibodies over time revealed a pattern dominated by
stable positivity. However, 10 patients lost reactivity
against 21OH during the follow-up period, and fluctua-
tion of indices were found for several other autoantibodies
such as tyrosine hydroxylase, SCC, IL-22, and GAD65
(Supplemental Figure 3).
AIRE genotype vs phenotype
We detected AIRE mutations in 44 patients. Two had
no mutations or copy number variations. Six deceased
patients were not tested, but genotypes could be deduced
based on their siblings. The most common mutation was
c.967_979del13 found in 45% of the alleles, followed by
c.769CT, and c.8791GA (Figure 3 and Supplemen-
talTable2).We thengrouped themaccording togenotype,
namely patients homozygous for missense mutations (ge-
notype 1; seven patients), patients homozygous for mu-
tations giving a truncated protein (genotype 2; 32 pa-
tients), and patients with one missense mutation and one
mutation giving a truncated protein (genotype 3; five pa-
tients). The splicing mutations were included in group 1.
The two patients without mutations (patients 49 and 50)
were excluded. The median number of disease manifesta-
tions was five in all groups. However, patients with ge-
notype 1 had a later disease onset (median age, 19 years)
than genotypes 2 and 3 (median age, 7 and 11 years, re-
spectively). Among patients with genotype 2, 90% had
CMC, and 75% had PAI. All patients with asplenia had
genotype 2. Three patients homozygous and one heterozy-
gous for the splicing mutation c.8791CG (patients 29,
30, 31, and 48) presented a mild phenotype with late dis-
ease onset (Figure 3 and Supplemental Table 2).
Immunotype vs phenotype
Seventeen (49%) of the patients with hypoparathyroid-
ism had autoantibodies against NACHT leucine-rich-re-
peat protein 5. Among patients with PAI, 93% had auto-
antibodies against 21OH, 63% against SCC, and 43%
against 17OH. All of the patients with autoantibodies
against 17OH also had autoantibodies against 21OH.
Both autoantibodies against 21OH and SCC correlated
significantly to PAI (P  .001 and P  .002, respectively).
Thirty patients with CMC (81%) had autoantibodies
against IL-22, giving a significant correlation (P  .004).
Autoantibodies against GAD65 were found in 22 patients,
including three patients with diabetes mellitus type 1.
Seven patients with vitiligo had autoantibodies against
Figure 2. Typical enamel hypoplasia in APS1. A, Hypomineralization
(white areas on front teeth) and enamel hypoplasia revealed by
horizontal hypoplastic bands. B, Severe enamel hypoplasia with loss of
normal enamel structure. C, Enamel hypoplasia varying in size and
location, affecting both front teeth and molars.
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AADC (88%), proving a significant correlation (P 
.047). Figure 4 presents a heat map with clinical manifes-
tations and previously reported correlated autoantibodies
grouped together.
HLA vs phenotype
The HLA class II genotype stratified to the risk of PAI
is given in Supplemental Table 2. However, 10 patients
with PAI had HLA class II alleles known to be protective
in the general population. We also found significantly
more alopecia in this group compared to the rest of the
cohort. None of the APS1 patients
with PAI carried the high-risk HLA
class II haplotype DR3-DQ2/
DR4.4-DQ8 (27).
Discussion
This longitudinal follow-up of the 52
Norwegian APS1 patients demon-
strates the clinical variability from
very mild to severe disease, occur-
rence of new components over time,
and an overall increased mortality
from adrenal crisis and cancer. Den-
tal examination revealed that enamel
hypoplasia was present in most pa-
tients and, together with CMC and
hypoparathyroidism, is one of the
three most common manifestations.
Longitudinal data have previously
been presented from the Finnish, Si-
cilian, and Sardinian patient cohorts
(with 91, 15, and 22 patients, respec-
tively) (21–23), which all represent
populations with strong founder ef-
fects (21, 23). The Norwegian pop-
ulation displays a greater genetic het-
erogeneity and may therefore be
more representative for the situation
in most countries.
The clinical variation and rarity of
APS1 makes the syndrome hard to
recognize. Since our latest report in
2007, only one child has been diag-
nosed, which is unexpected because
we estimate that at least one child
every other year is born with APS1 in
Norway (3). The reason is unclear,
but most likely disease components
are being recognized and treated,
whereas the syndrome goes undiag-
nosed. Alternatively, patients die during childhood with-
out diagnosis, as indeed was observed in seven of our pa-
tients. This underscores the importance of increased
awareness and early diagnosis. APS1 should be considered
in all patients presenting one of the major clinical mani-
festations, especially when it presents in childhood. More-
over, when a new patient is diagnosed, all siblings should
be offered genetic counseling.
Some variation in the frequency of disease components
occurs among APS1 cohorts. We report several with hy-
pothyroidism, which is also found in Apulian APS1 pa-
Figure 3. AIRE mutations in Norwegian APS1 patients. A, Overview of the identified mutations
and their frequencies. B, Location of AIRE mutations in Norwegian APS1 patients together with a
schematic representation of the AIRE protein and its functional domains. Boxes 1–14 represent
the exons, and the different mutations are given in the text boxes above. CARD/HSR, Caspase
recruitment domain/homodimerization domain (amino acids 1–105); NLS, nuclear localization
signal (amino acids 100–189); SAND, Sp100, AIRE-1, NucP41/75 (181–280), DEAF-1; L (LXXLL),
nuclear receptor-binding motifs (amino acids 7–11, 63–67, 414–418, 516–520); PHD, plant
homeodomain type zinc fingers (amino acids 296–343 and 434–475); PRR, proline-rich region
(amino acids 350–430).
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tients (28). However, hypothyroidism was not seen in the
Sardinian patients (23), although late onset cannot be ex-
cluded (2). Although autoimmune cause was not proved,
it is probably caused by autoimmunity given the propen-
sity for autoimmunity in APS1. Furthermore, autoim-
mune hepatitis was described as a serious and early feature
in 27% of the Sardinian patients (23), whereas we found
hepatitis in only two (4%). In a study of 23 Persian Jews
(11), 22 presented with hypoparathyroidism, and only
four patients had oral CMC. The Sardinian patients dis-
played the most severe phenotype, with a mean of seven
disease manifestations per patient and early disease onset
(23). Besides the different AIRE genotypes, other immune
genes might potentially affect the phenotype (29), and en-
vironmental factors and varying practices among clini-
cians may also have influence.
Poorly treated or undiagnosed endocrinopathies as
part of APS1, especially PAI, hypoparathyroidism, and
diabetes mellitus type 1, can be fatal. Adherence to ther-
apy, especially in teenage patients, is challenging. An in-
creased death risk and altered cancer incidence pattern
have been described (4). Identifying risk factors for ma-
lignancies and minimizing these by treatment of CMC and
avoidance of smoking are probably important (21). In
addition, pneumococcal vaccination must be performed in
patients with asplenia and should probably be offered to
all APS1 patients.
All of the Norwegian patients had organ-specific au-
toantibodies. Typically, the presence of autoantibodies
correlates to clinical manifestations but may appear years
before the corresponding clinical manifestation (3, 14, 18,
19). A correlation between gonadal failure and autoanti-
bodies against SCC is reported (14, 30), which was also
found in five of the nine female patients with gonadal
failure in this study. In total, SCC autoantibodies were
found in 21 patients. Autoantibodies against GAD65 are
normally known to correlate with diabetes mellitus type 1
(31), but this is not the case in APS1 (14). We found
GAD65 autoantibodies in three of four diabetic patients
and in 19 patients without diabetes. No correlation with
autoantibodies against GAD65 and vitiligo or malabsorp-
tion was found, in conflict with an earlier report (14).
However, autoantibodies against AADC correlated with
vitiligo, and autoantibodies against 21OH and SCC cor-
related with PAI. Autoantibodies against the prostate-spe-
cific enzyme TGM4 were only seen in the males, consistent
with a recent report (15).
We found antibodies against IFN- in a similar pro-
portion to that in other APS1 cohorts (21–23). These au-
toantibodies are often found in the earliest samples; they
persist for decades and show a high specificity for APS1
(19, 32). IFN autoantibodies can also be found in low titer
in diseases causing an increased IFN production (ie, sys-
temic lupus erythematosus, human immunodeficiency vi-
rus, and hepatitis C virus infections), as well as in myas-
thenia gravis (33). Two female patients did not present
AIRE mutations or IFN- autoantibodies but fulfilled the
clinical criteria. They may have mutations either in the
regulatory parts of the AIRE gene or in other genes in the
same pathway, or they may be phenocopies. Another pa-
tient presented all three major disease components from
childhood and was compound heterozygous (c.22CT/
c.967_979del13) for two AIRE mutations, but autoanti-
bodies against IFN- were not found.
The cohort presented here is older and has a much
greater genetic heterogeneity compared to other APS1 co-
Figure 4. Heat map of clinical manifestations and autoantibodies in Norwegian APS1 patients. Family number and patient number are given in
the first two rows. A black square represents a disease manifestation, and a gray square represents positive autoantibodies. If the square is dotted,
the examination/analyses are not performed; a white square represents negative disease component/AIRE mutation/autoantibodies that are
tested for.
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horts. Of particular interest was the c.8791CG splice
mutation found in three homozygous patients (patients
29, 30, and 31), who all had ancestors in a particular
district of Western Norway. Their phenotypes were char-
acterized by late disease onset and generally a milder phe-
notype. The three patients had their first manifestation at
15, 19, and 23 years of age. The two patients with hypo-
parathyroidism developed hypocalcemia at 43 and 60
years of age. It is not known whether this implies that the
splice defect is not complete and that some residual AIRE
function is present.
We found 10 patients with PAI carrying HLA class II
alleles known to protect against PAI in the general popu-
lation (27). Patients in this group also had significantly
more alopecia (P  .05). In contrast, none of the APS1
patients with PAI carried the HLA class II haplotype DR3-
DQ2/DR4.4-DQ8, which is by far the strongest predis-
posing genetic factor for autoimmune PAI. Moreover,
three out of four patients with diabetes carried the
DQB1*0602 allele, which is otherwise extremely rare in
type 1 diabetes. Although many of these patients are rel-
atives, this indicates that the known risk stratification for
HLA is overridden by the effect of the AIRE mutations, in
contrast to previous findings (29).
In conclusion, the increasing knowledge about clinical
variation, AIRE, and autoimmunity seems to expand and
redefine APS1. However, the diagnosis should be consid-
ered in all patients presenting one of the major clinical
manifestations, especially when it first presents in child-
hood. Nonendocrine components such as enamel hyp-
oplasia and CMC are common and should trigger further
diagnostic workup. Autoantibodies against IFN- are
usually present, but their absence does not exclude the
diagnosis. The AIRE gene should be sequenced if clinical
suspicion is high. When a patient is diagnosed, all siblings
should be investigated because late onset is common. We
recommend regular surveillance in a specialized center be-
cause it can reduce morbidity and mortality.
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